Binghamton University Secures Funding for AI-Powered Cancer Detection and Advanced RNA Drug Delivery

Binghamton University Secures SUNY Funding for Healthcare Innovations

Binghamton University researchers Nancy Guo and John Fetse have secured seed funding through the SUNY Technology Accelerator Fund (TAF) to advance two critical medical technologies addressing AI for cancer diagnostics and RNA therapeutic drug delivery1

1

2

2

. The funding comes as part of a $400,000 allocation split among five SUNY universities, including Albany, Buffalo, Stony Brook, and Upstate Medical University, designed to accelerate commercialization of innovations with market potential1

1

. State University of New York Chancellor John B. King Jr. emphasized that SUNY continues to lead in interdisciplinary research that develops state-of-the-art technologies and serves the public good2

2

.

ClinSegAI: AI-Powered Early Cancer Diagnosis Through Pathology Imaging

Professor of Empire Innovation Nancy Guo from the Thomas J. Watson College of Engineering and Applied Science's School of Computing received TAF funding to develop ClinSegAI, a predictive model that uses artificial intelligence to detect biomarkers within standard pathology imaging1

1

. The technology aims to rapidly reduce treatment decision time, marking a significant improvement in patient care standards. Guo explained that the medical imaging analysis model will incorporate molecular biology insights to identify early indicators of tumor progression, potentially detecting changes before they become visible through conventional radiological assessment2

2

. This approach to early cancer diagnosis could transform how clinicians make critical treatment decisions by providing faster, more accurate biomarker identification.

PeptoLNP: Addressing RNA Therapeutic Drug Delivery Challenges

Assistant Professor of Pharmaceutical Sciences John Fetse from the School of Pharmacy and Pharmaceutical Sciences secured funding to advance his research on RNA therapeutics through a novel delivery system called PeptoLNP1

1

. Current methods using lipid nanoparticles have poor delivery efficiency and raise toxicity concerns that limit proper dosing, but Fetse has overcome these challenges by incorporating amino acids directly into the lipids2

2

. These amino acid-based lipid nanoparticles reduce toxicity risk while improving delivery rates. Fetse noted that RNA medicines hold enormous promise for diseases that have long had no effective treatment, but delivering them safely to the right place in the body remains one of medicine's biggest unsolved challenges1

1

. The PeptoLNP technology is built from amino acids, making it naturally biodegradable and adaptable for targeting different tissues, which could generate the evidence needed to move the technology out of the lab and toward patients2

2

.

Market Readiness and Commercialization Path Forward

The SUNY Technology Accelerator Fund supports critical research activities including feasibility studies, prototyping, and testing that demonstrate an idea or innovation has commercial potential1

1

. The program's goal is to accelerate time-to-market for these innovations and increase their market readiness for potential investors, strategic partners, and customers. Binghamton University President Anne D'Alleva praised both researchers for developing new technologies that could have a real impact on delivering timely, safer, and more effective treatments for people suffering from a variety of diseases2

2

. The funding will help move these discoveries beyond the lab and closer to people who could actively benefit from them, addressing important health challenges through research that tackles both diagnostic speed and therapeutic safety. Watch for clinical trial announcements as both ClinSegAI and PeptoLNP progress through feasibility studies and prototyping phases toward potential market entry.